U.S. Markets open in 1 hr 41 mins

Recent Developments for Portola Pharmaceuticals

Daniel Collins
Recent Developments for Portola Pharmaceuticals

In September 2018, the US FDA granted Portola Pharmaceuticals’ cerdulatinib, an investigational Syk/JAK inhibitor, an orphan drug designation for peripheral T-cell lymphoma (or PTCL) therapy. The FDA grants this designation to support the development of therapies for rare diseases. This designation provides benefits such as seven years of market exclusivity after approval, tax credits for certain clinical trials, and exemption of FDA application fees.